Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells-Reference-Cited by-同舟云学术

Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells

Published:2022-08-05 Issue:8 Volume:45 Page:550-563
ISSN:0219-1032
Container-title:Molecules and Cells
language:en
Short-container-title:Mol.Cells

Author:

Park Mijin¹²^ORCID,Moon Byul¹²^ORCID,Kim Jong-Hwan³^ORCID,Park Seung-Jin¹²^ORCID,Kim Seon-Kyu¹²^ORCID,Park Kihyun⁴^ORCID,Kim Jaehoon⁴^ORCID,Kim Seon-Young¹³^ORCID,Kim Jeong-Hoon¹⁵^ORCID,Kim Jung-Ae¹²^ORCID

Affiliation:

1. Department of Functional Genomics, Korea Research Institute of Bioscience and Biotechnology (KRIBB) School of Bioscience, University of Science and Technology, Daejeon 34113, Korea

2. Personalized Genomic Medicine Research Center, KRIBB, Daejeon 34141, Korea

3. Korea Bioinformation Center, KRIBB, Daejeon 34141, Korea

4. Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon 34141, Korea

5. Disease Target Structure Research Center, KRIBB, Daejeon 34141, Korea

Publisher

Korean Society for Molecular and Cellular Biology

Subject

Cell Biology,Molecular Biology,General Medicine

Link

http://pdf.medrang.co.kr/KSMCB/2022/045/KSMCB045-08-06.pdf

Reference50 articles.

1. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma